ClinicalTrials.gg
CompletedNCT00214942Updated May 9, 2014

Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for Management of Breakthrough Pain

A Phase 3 interventional study of ORAVESCENT Fentanyl Citrate in Chronic Low Back Pain, sponsored by Cephalon. Completed at 17 sites in United States. Open to participants aged 18 Years to 80 Years. Per ClinicalTrials.gov, last updated 2014-05-09.

Sponsored by Cephalon (part of Teva Pharmaceutical Industries, Ltd.) · Phase 3, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Allocation
Randomized
Ages
18 Years to 80 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 712 studies in Low Back Pain with a site in United States — 100 open to participants now, 126 under way, 3 of them phase 3. Low Back Pain · United States.

Started
2005
with 12 others
Phase 3
62 of 712
1 open now
Registered
23rd of 712
by date

Among the 712 studies in Low Back Pain with a site in United States, this one is one of 13 that started in 2005, is one of 62 in phase 3, and was the 23rd registered.

Low Back Pain

2,929 studies on the registry are indexed under Low Back Pain; 580 are open to participants now.

Browse Low Back Pain studies →

Open to participants now

100 of the 712 studies in Low Back Pain with a site in United States are open now. Recruiting first, the newest first:

95 more — sign in →

All 100 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 332 Low Back Pain studies recruiting now, 93 (28%) set no upper age limit and 209 (63%) stop at 75 or younger; 8 take children under 18; 46 take healthy volunteers.

This study: 18 Years to 80 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 712 studies in Low Back Pain with a site in United States, or all of them as a file.
02

Study summary

A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Efficacy and Safety of ORAVESCENT Fentanyl Citrate for Management of Breakthrough Pain in Opioid-Tolerant Patients with Chronic Low Back Pain

03

Conditions studied

  • Chronic Low Back Pain

Browse trials for

04

Who can participate

Ages eligible
18 Years to 80 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

Patients are included in the study if all of the following criteria are met:

  • The patient is willing to provide written to participate in this study.
  • The patient is 18 through 80 years of age.
  • Women must be surgically sterile, 2 years , or, if of , using a medically accepted method of (ie, barrier method with spermicide, steroidal contraceptive [oral, transdermal, implanted, or injected contraceptives must be used in conjunction with a barrier method], or intrauterine device [IUD]) and agree to continued use of this method for the duration of this study.
  • The patient has a diagnosis of chronic low back pain, resulting in functional disability of at least 3 months duration and is associated with any of the following: osteoarthritis, degenerative disc disease, or spondylolisthesis. Patients with other low back pain etiologies may qualify for the study with permission from the Cephalon medical monitor or designee.
  • The patient is currently using 1 of the following: at least 60 mg/day or oral morphine/day, or at least 25 mcg transdermal fentanyl/hour, or at least 30 mcg oxycodone/day, as a stable dose of around-the-clock (ATC) therapy for at least the previous 7 days before enrollment into the study.
  • The patient reports an average pain intensity score, over the prior 24 hours, of less than 7 (0=no pain through 10=worst pain) for their chronic low back pain.
  • The patient experiences, on average, 1 to 4 BTP episodes (defined as temporary flares of severe or excruciating pain) per day while taking ATC opioid therapy, and on average, the duration of each BTP episode is less than 4 hours.
  • The patient currently uses opioid therapy for alleviation of BTP episodes, occuring at the location of the chronic pain, and achieves at least partial relief.
  • The patient is able to effectively self-administer the study drug.

Exclusion criteria

Exclusion Criteria:

Patients are excluded from participating in this study if 1 or more of the following criteria are met:

  • The patient has uncontrolled or rapidly escalating pain as determined by the investigator (ie, the ATC therapy may be expected to change between the first and last treatments with study drug), or has pain uncontrolled by therapy that could adversely impact the safety of the patient or that could be compromised by treatment with study drug.
  • The patient has known or suspected , allergies, or other to any ingredient in the study drug.
  • The patient has a recent history (within 5 years) or current evidence of alcohol or other substance abuse.
  • The patient has cardiopulmonary disease that would, in the opinion of the investigator, significantly increase the risk of treatment with potent synthetic opioids.
  • The patient has medical psychiatric disease that, in the opinion of the investigator, would compromise collected data.
  • The patient is expected to have surgery during the study and it is anticipated that the surgery will alleviate the patient's pain.
  • The patient has had therapy before study drug treatment that, in the opinion of the investigator, could alter pain or response to pain medication.
  • The patient is pregnant or lactating.
  • The patient has participated in a previous study with ORAVESCENT fentanyl.
  • The patient has participated in a study involving an drug in the previous 30 days.
  • The patient has received a monoamine oxidase inhibitor (MAOI) within 14 days before the first treatment with study drug.
  • The patient has any other medical condition or is receiving concomitant medication/therapy (eg, regional nerve block) that would, in the opinion of the investigator, compromise the patient's safety or compliance with the study protocol, or compromise collected data.
  • The patient is involved in active litigation in regard to their chronic pain.
  • The patient has a positive urine drug screen (UDS) for a medication not prescribed by their physician or no reasonable explanation can be provided to the Cephalon medical monitor.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Factorial assignment
Masking
Double

Interventions

  • DrugORAVESCENT Fentanyl Citrate
06

Study locations

17 sites
  • Clopton Clinic
    Jonesboro, Arkansas 72401, United States
  • Vertex Clinical Research, Inc.
    Bakersfield, California 93311, United States
  • San Diego Arthritis Medical
    San Diego, California 92106, United States
  • Clinical Research of W Florida
    Clearwater, Florida 33765, United States
  • Florida Institute of Medical R
    Jacksonville, Florida 32207, United States
  • Clinical Pharmacology Services
    Tampa, Florida 33617, United States
  • Gold Coast Research
    Weston, Florida 33331, United States
  • Center for Prospective Outcome
    Marietta, Georgia 30060, United States
  • Georgia Medical Research
    Marietta, Georgia 30060, United States
  • American Medical Research
    Chicago, Illinois 60616, United States
  • American Medical Research
    Oak Brook, Illinois 60523, United States
  • American Medical Research
    Valparaiso, Indiana 46383, United States
  • Iowa Pain Management Clinic, P
    Des Moines, Iowa 50265, United States
  • Mid America Physiatrists, PA
    Overland Park, Kansas 66211, United States
  • Best Clinical Trial, Inc.
    New Orleans, Louisiana 70115, United States
  • PharmQuest
    Greensboro, North Carolina 27401, United States
  • Northwest Clinical Research
    Bellevue, Washington 98004, United States
07

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Sep 2005 and a primary completion of Mar 2006. It does not say whether these dates are actual or estimated.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 14, 2005
First posted
Sep 22, 2005
Start
Sep 2005
Primary completionActual
Mar 2006
Last update
May 9, 2014
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on May 9, 2014, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
08

Registry details

Key details

Study ID
NCT00214942
Lead sponsor
Cephalon
Responsible party
Sponsor
First posted
Sep 22, 2005
Start date
Sep 2005
Primary completion
Mar 2006
Last update
May 9, 2014
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2014. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion